Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVM13R)

• Drug Name: LJPC-401 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Beta thalassemia	3A50.2	Phase 2	[1]
Hemochromatosis	5C64.1Y	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DMVM13R

Molecule-Related Drug Atlas

Drug(s) Targeting Hepcidin (HAMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NOX-H94	DM5HPZU	Anemia	3A00-3A9Z	Phase 2	[3]
PTG-300	DMOYS8A	Hemochromatosis	5C64.1Y	Phase 2	[4]
Hepcidin mab	DMBFYSR	Anemia	3A00-3A9Z	Phase 1	[5]
LY2787106	DM9NYHT	Anemia	3A00-3A9Z	Phase 1	[6]
12B9m	DM5IUN8	Anaemia	3A90	Preclinical	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepcidin (HAMP)	TTPCG5T	HEPC_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT03381833) A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health.
• [3] The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013 Mar 21;121(12):2311-5.
• [4] Clinical pipeline report, company report or official report of Protagonist Therapeutics.
• [5] The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161.
• [6] A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73.
• [7] Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 2010 Dec;12(4):646-57.